



الجزيرة للصناعات الدوائية
Jazeera Pharmaceutical Industries

15/12/2014

Direct Healthcare Professional Communication on restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Lisinopril (Zinopril®)

Dear Healthcare Professional,

Jazeera Pharmaceutical Industries (JPI) would like to inform you about restrictions on combining different classes of medicines that act on the renin-angiotensin aldosterone system (RAAS), a hormone system that controls blood pressure and the volume of fluids in the body. This group of medicines (called RAAS-acting agents) has three main classes: angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-inhibitors) and direct renin inhibitors such as aliskiren. Combination of medicines from any two of these classes should not be used and, in particular, in patients with diabetes mellitus or renal impairment.

information on the safety Concern

- Combination therapy of direct renin inhibitors such as aliskiren with ACEI or ARB may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.
- Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.
- If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

The information in this letter has been approved by the Saudi Food and Drug Authority.

The Summary of Products Characteristics (SPC) and patient leaflet of Zinopril® in Saudi Arabia will be updated shortly to reinforce the safety of treated patients.



الجزيرة للصناعات الدوائية
Jazeera Pharmaceutical Industries

Call for reporting

As a reminder, there is a need to report any suspected adverse reactions to the National Pharmacovigilance and Drug Safety Center (NPC):

By email: npc.drug@sfda.gov.sa
Or by fax: +966 11 2057662
Or by online: <https://ade.sfda.gov.sa/>

Pharmacovigilance department in JPI:

Patient safety is a top priority for JPI. You can assist for monitoring the safety of Zinopril® (Lisinopril) by reporting suspected adverse events associated with the use of Zinopril® to:

Pharmacovigilance department on:
Fax: +966 11 2078097
Email: medical@jpi.com.sa

Yours sincerely,

Alaa M. Alosaimi
Medical Affairs senior officer
Jazeera Pharmaceutical Industries (JPI)